Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. develops and commercializes medicines for genetic conditions through a decentralized biopharmaceutical model. News for BBIO centers on Attruby/acoramidis, its oral transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM), including clinical data from ATTRibute-CM, commercial updates, Brazil marketing authorization under the BEYONTTRA name, and licensing or commercialization arrangements.
Company updates also cover late-stage genetic-disease programs such as encaleret for autosomal dominant hypocalcemia type 1, BBP-418 for limb-girdle muscular dystrophy type 2I/R9, and oral infigratinib for achondroplasia. Recurring financial and corporate items include quarterly results, product revenue trends, capital actions, employee equity inducement grants, investor conference participation, and pipeline regulatory disclosures.
Bristol Myers Squibb (NYSE:BMY) is highlighted in a broader look at AI-driven cardiology and novel cardiac therapies. The company reported positive Phase 3 SCOUT-HCM results for Camzyos in adolescents with obstructive hypertrophic cardiomyopathy, meeting the primary endpoint with a -48.0 mm Hg Valsalva LVOT gradient difference vs placebo (P < 0.0001).
No patients experienced left ventricular ejection fraction below 50%. Camzyos is already approved for adult oHCM in over 60 countries and prescribed to more than 22,000 U.S. patients, positioning BMY to potentially seek a pediatric label expansion in a population without targeted therapies.
BridgeBio (Nasdaq: BBIO) submitted a New Drug Application to the FDA for encaleret to treat autosomal dominant hypocalcemia type 1 (ADH1).
The Phase 3 CALIBRATE trial met all primary and key secondary endpoints, with 76% on encaleret vs 4% on conventional therapy achieving target serum and urine calcium. Encaleret may be eligible for priority review, with an anticipated U.S. launch in early 2027 and an EMA MAA planned for 2H 2026. Pediatric and chronic hypoparathyroidism Phase 2/3 and Phase 3 programs are also underway.
BridgeBio Pharma (Nasdaq: BBIO) reported new Phase 3 ATTRibute-CM data showing that acoramidis increased serum transthyretin (sTTR) early and significantly reduced intra-individual sTTR variability versus placebo, both linked to lower all-cause mortality. Acoramidis also cut outpatient worsening heart failure risk by 41% and reduced cardiovascular hospitalizations by 34% versus tafamidis in an indirect comparison.
The therapy consistently blunted NT-proBNP increases, preserved Kansas City Cardiomyopathy Questionnaire scores, and improved or maintained heart failure-related health status. Acoramidis, a near-complete (≥90%) TTR stabilizer, is approved as Attruby in the US and BEYONTTRA in multiple global markets for ATTR-CM.
BridgeBio Pharma (Nasdaq: BBIO) announced on May 8, 2026 that its compensation committee approved inducement equity grants for 52 new employees totaling 115,007 restricted stock units. One-quarter vests on May 16, 2027, then one‑twelfth of the remainder vests quarterly thereafter, subject to continued employment. Awards were granted under the company’s equity plan adopted November 2019 and amended February 10, 2023 and December 13, 2023, in compliance with Nasdaq Listing Rule 5635(c)(4).
BridgeBio (NASDAQ: BBIO) reported $194.5M total revenue for Q1 2026, including $180.6M of U.S. Attruby net product revenue, and $940.2M in cash, cash equivalents and marketable securities as of March 31, 2026. The Board authorized a $500M share repurchase program.
Pipeline updates: NDA submitted for BBP-418 (LGMD2I/R9); encaleret NDA planned 1H 2026; infigratinib NDA planned Q3 2026. Attruby approvals expanded (Brazil) and new survival and real-world data presented at major meetings.
BridgeBio (Nasdaq: BBIO) announced management will participate in investor fireside chats at three healthcare conferences in May–June 2026: BofA Health Care Conference (May 12, 2:20 pm PDT), Jefferies Global Healthcare Conference (June 4, 11:05 am EDT), and Goldman Sachs Global Healthcare Conference (June 9, 8:00 am EDT).
Live webcasts will be available via the company’s Events and Presentations investor page and replays will remain online for 90 days after each event.
BridgeBio (Nasdaq: BBIO) announced ANVISA approval of BEYONTTRA (acoramidis) to treat wild-type or variant transthyretin amyloidosis cardiomyopathy (ATTR-CM) in adults in Brazil. Approval follows the Phase 3 ATTRibute-CM trial (632 patients) showing a 42% reduction in composite all-cause mortality and recurrent CV hospitalization and a 50% reduction in cumulative CV hospitalizations at Month 30. BEYONTTRA is described as a near-complete (≥90%) TTR stabilizer and already carries approvals in the U.S., EU, UK, Switzerland, and Japan. Commercialization in Brazil is planned with Biopas beginning in H2 2026.
BridgeBio (NASDAQ: BBIO) will present primary Phase 3 CALIBRATE results for encaleret in autosomal dominant hypocalcemia type 1 (ADH1) at the 2026 European Congress of Endocrinology (ECE) in Prague.
Presentations include two oral talks (May 12), one poster (P72) and one ePoster (EP260); presenters include Filomena Cetani and Arun Mathew.
BridgeBio (NASDAQ: BBIO) announced presentations of new Phase 3 ATTRibute-CM data for acoramidis at ESC-Heart Failure 2026 in Barcelona on May 9–12, 2026.
Highlights include a late-breaking oral presentation by Bayer on outpatient worsening heart failure, data on NT-proBNP at Month 30, and KCCQ-OS quality-of-life results.
BridgeBio (Nasdaq: BBIO) will report first quarter 2026 financial results and provide commercial and program updates after market close on Thursday, May 7, 2026.
A conference call and live webcast will begin at 4:30 pm ET. A replay will be available on the company website for 30 days.